






ACURATE neo2 vs. Evolut PRO/PRO+

Results from NEOPRO-2: A retrospective registry of 2175 TAVR patients with either ACURATE neo2 (N=763) or Evolut PRO/PRO+ (N=1421)




TAVR with ACURATE neo2 vs Evolut PRO/PRO+ Insights from the NEOPRO-2 registry

N=2,175
20 centres
VARC-3-defined outcomes



When compared to Evolut PRO/PRO+, **ACURATE neo2** demonstrated:

Higher rates of early safety - driven by significantly lower rates of PPI & Lower rates of moderate-severe PAR, even in heavily calcified aortic valves



*Analysis performed in the overall cohort as well as propensity-score (PS) matched cohorts